Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan

March 10, 2015

All proposals related to Actavis' planned acquisition of Allergan were approved by both Actavis' and Allergan's shareholders.

PRESS RELEASE

DUBLIN

and

IRVINE, Calif.

,

March 10, 2015

/PRNewswire/ --

Actavis plc

(NYSE: ACT) and

Allergan, Inc.

(NYSE: AGN)

announced that, at shareholder meetings held today, all proposals related to

Actavis'

planned acquisition of

Allergan

were approved by both

Actavis'

and

Allergan's

shareholders.

Actavis'

and

Allergan's

shareholder approvals satisfy certain conditions to the closing of the transaction.

The closing of the transaction is expected to occur late in the first quarter or early in the second quarter of 2015, subject to the satisfaction or waiver of certain regulatory approvals and other customary closing conditions.

About

Actavis

About

Actavis plc

(NYSE:ACT), headquartered in

Dublin, Ireland

, is a

unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality

affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis

markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women's health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications.

Actavis

has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit

Actavis'

website at

www.actavis.com

.

About

Allergan

Allergan

is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have approximately 10,500 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, and urologics,

Allergan

is proud to celebrate more than 60 years of medical advances and proud to support the patients and customers who rely on our products and the employees and communities in which we live and work.

For more information regarding

Allergan

, go to:

www.allergan.com

.